- Patients
- Clinical Research
- Clinical trials
- 102 Hummingbird
Solid Tumours
102 Hummingbird
A study of an Anti-HER3 Antibody, HMBD-001, With or without Chemotherapy in Patients with Solid Tumours Harboring an NRG1 Fusion or HER3 Mutation Phase 1b HER3 inhibitor NRG1 fusions (panc, NSCLC) and SCC studies
Trial overview
Medical Oncology
Solid Tumours
1b
Number: NCT05919537
https://clinicaltrials.gov/study/NCT05919537?term=HMBD-001-102%20&rank=1
North Shore
North Shore Health Hub, Tower A, Level 1, 7 Westbourne St, St Leonards, NSW, 2065, Australia
(02) 8037 4100 admin.northshore@genesiscare.comMedical Oncologist
Prof. Nick Pavlakis
BSc MBBS MMed PhD FRACP
Frenchs Forest (Oncology) +1
Disclaimer:
This website is provided for information purposes only. Nothing on this website is intended to be used as medical advice, or to diagnose, treat, cure or prevent any disease. It should not be used as a substitute for your own health professional's advice. Any medical procedure or treatment carries risks. Before proceeding with treatment, you should discuss the risks and benefits of the treatment with an appropriately qualified health practitioner. Individual treatment outcomes and experiences will vary.